Neurocrine Biosciences Inc(NBIX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:09 PM ET (Korea 10/31 06:09)
Full metrics table
| Index | - | P/E | 21.4 | EPS (ttm) | 6.83 | Insider Own | 1.21% | Shs Outstand | 101.6M | Perf Week | 2.38% |
| Market Cap | 14.85B | Forward P/E | 15.32 | EPS next Y | 34.03% | Insider Trans | -24.57% | Shs Float | 100.4M | Perf Month | 3.83% |
| Enterprise Value | 14.86B | PEG | 0.41 | EPS next Q | 1.91 | Inst Own | 102.52% | Short Float | 6.42% | Perf Quarter | -12.11% |
| Income | 0.71B | P/S | 4.4 | EPS this Y | 52.36% | Inst Trans | -0.79% | Short Ratio | 4.93 | Perf Half Y | 10.87% |
| Sales | 3.37B | P/B | 4.02 | EPS next 5Y | 37.4% | ROA | 15.26% | Short Interest | 6.45M | Perf YTD | 3.01% |
| Book/sh | 36.35 | P/C | 38.1 | EPS past 3/5Y | 44.05% 2.31% | ROE | 22.09% | 52W High | -21.5% ($186.12) | Perf Year | 5.84% |
| Cash/sh | 3.83 | P/FCF | 18.29 | Sales past 3/5Y | 24.32% 22.29% | ROIC | 17.23% | 52W Low | 19.62% ($122.14) | Perf 3Y | 36.38% |
| Dividend Est. | - | EV/EBITDA | 17.41 | EPS Y/Y TTM | 102.44% | Gross Margin | 97.48% | Volatility(W/M) | 2.11% 2.36% | Perf 5Y | 38.6% |
| Dividend TTM | - | EV/Sales | 4.41 | Sales Y/Y TTM | 34.42% | Oper. Margin | 23.9% | ATR (14) | 3.45 | Perf 10Y | 229.2% |
| Dividend Ex-Date | - | Quick Ratio | 1.75 | EPS Q/Q | 30.2% | Profit Margin | 20.91% | RSI (14) | 55.46 | Recom | 1.39 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.87 | Sales Q/Q | 39.49% | SMA20 | 2.96% ($141.9) | Beta | 0.37 | Target Price | $207.37 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/11/2 | SMA50 | -0.36% ($146.63) | Rel Volume | 1.01 | Prev Close | $146.38 |
| Employees | 2000 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | -15.73% 7.61% | SMA200 | -0.87% ($147.38) | Avg Volume(3M) | 1.31M | Price | $146.1 |
| IPO | 1996/5/23 | Option/Short | Yes/Yes | Trades | 19900 | Volume | 1,322,831 | Change | -0.19% |
A biopharmaceutical company that develops and sells treatments for neurological/psychiatric and endocrine disorders. Its core product is a movement-disorder therapy, and it maintains a drug pipeline in the neuropsychiatric and endocrine fields. It is one of the leading biopharmaceutical companies with commercialization capabilities and a pipeline specialized in neuroscience.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
Traded about as much as usual. That is 101% of its average volume.
Next earnings report: November 2
1 days to go.
NBIX makes money exceptionally well
Of every $100 in sales, $23.90 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +52.4% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $1,532. Peers typically go for $1,519. Compared with its own 5-year average, it is 49% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +38.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 102.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #7 of 83 in the industry
Based on market cap of $15B.
UTHR#5 United Therapeutics Corp $26B PER 21.4 
VTRS#6 Viatris Inc $22B PER - NBIX#7 Neurocrine Biosciences Inc $15B PER 21.4 
RDY#8 Dr. Reddy's Laboratories Ltd ADR $12B PER 38.9 
ELAN#9 Elanco Animal Health Inc $12B PER - 
FAQ
What kind of company is NBIX?
NBIX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of NBIX?
The market cap of NBIX is approximately $14.9B, ranking 720 within its sector.
What is the P/E ratio of NBIX?
NBIX has a P/E ratio of approximately 21.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for NBIX?
NBIX has recorded a 52-week high of $186.12 and a low of $122.14.
